Radar HealthTech | Sdli
  • Sdli
  • Nuestros Clientes
  • Nuestro equipo
  • Radar Sdli
  • Blog Sdli
  • Escríbenos!
Seleccionar página

Pre-diagnostic cognitive and functional impairment in multiple sporadic neurodegenerative diseases

por Sdli Scouter | Oct 18, 2022 | Diagnostic Tools

Summary: «The pathophysiological processes of neurodegenerative diseases begin years before diagnosis. However, pre-diagnostic changes in cognition and physical function are poorly understood, especially in sporadic neurodegenerative disease.» «There was evidence for...

Digital Health in Pain Management

por Sdli Scouter | Oct 17, 2022 | Digital Patient, Sector and Trends

Summary: «Pain is defined by the International Pain Society (IASP) as “An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.” An estimated 1 in 5 people globally experience some form of...

Diagnostic Performance of Deep Learning in Infectious Keratitis: A Systematic Review and Meta-Analysis Protocol

por Sdli Scouter | Oct 17, 2022 | Diagnostic Tools

Summary: «Infectious keratitis (IK) represents the 5th leading cause of blindness worldwide. A delay in diagnosis is often a major factor in progression to irreversible visual impairment and/or blindness from IK. The diagnostic challenge is further compounded by low...

La inteligencia artificial que mitiga el malestar menstrual gracias a un diseño sonoro basado en neurociencia

por Sdli Scouter | Oct 14, 2022 | Digital Patient

Summary: «Moonai ha desarrollado sonidos que ayudan a las mujeres a combatir los efectos de la menstruación y a potenciar su productividad y bienestar durante el ciclo según sus necesidades en cada momento.» «La tecnología tiene como finalidad última mejorar la...

4Moving Biotech Announces First Patient Enrolled in Phase I Clinical Trial on Osteoarthritis

por Sdli Scouter | Oct 14, 2022 | Sector and Trends, Startups

Summary: » «We are so excited to have the first patient enrolled in our first-in-human phase 1 clinical study. This initial step is critical to evaluate the safety and tolerability of our OA drug candidate”, said Francis Berenbaum, co-founder and CEO/CMO of 4Moving...
« Entradas más antiguas
Entradas siguientes »

© -2026 | Sdli